Share-based Payment Arrangement, Expense of Taysha Gene Therapies, Inc. from 30 Sep 2020 to 30 Sep 2025

Taxonomy & unit
us-gaap: USD
Description
Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.
Summary
Taysha Gene Therapies, Inc. quarterly and annual Share-based Payment Arrangement, Expense in USD history and change rate from 30 Sep 2020 to 30 Sep 2025.
  • Taysha Gene Therapies, Inc. Share-based Payment Arrangement, Expense for the quarter ending 30 Sep 2025 was $3,285,000, a 2.1% decline year-over-year.
  • Taysha Gene Therapies, Inc. Share-based Payment Arrangement, Expense for the twelve months ending 30 Sep 2025 was $12,985,000, a 9.5% increase year-over-year.
  • Taysha Gene Therapies, Inc. annual Share-based Payment Arrangement, Expense for 2024 was $13,103,000, a 66% increase from 2023.
  • Taysha Gene Therapies, Inc. annual Share-based Payment Arrangement, Expense for 2023 was $7,905,000, a 56% decline from 2022.
  • Taysha Gene Therapies, Inc. annual Share-based Payment Arrangement, Expense for 2022 was $18,043,000, a 0.78% decline from 2021.
Source SEC data
View on sec.gov
Share-based Payment Arrangement, Expense, Trailing 12 Months (USD)
Share-based Payment Arrangement, Expense, Quarterly (USD)
Share-based Payment Arrangement, Expense, YoY Quarterly Change (%)
Share-based Payment Arrangement, Expense, Annual (USD)
Share-based Payment Arrangement, Expense, YoY Annual Change (%)

Taysha Gene Therapies, Inc. Quarterly Share-based Payment Arrangement, Expense (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
Q3 2025 $12,985,000 $3,285,000 -$72,000 -2.1% 01 Jul 2025 30 Sep 2025 10-Q 04 Nov 2025 2025 Q3
Q2 2025 $13,057,000 $3,190,000 -$142,000 -4.3% 01 Apr 2025 30 Jun 2025 10-Q 12 Aug 2025 2025 Q2
Q1 2025 $13,199,000 $3,294,000 +$96,000 +3% 01 Jan 2025 31 Mar 2025 10-Q 15 May 2025 2025 Q1
Q4 2024 $13,103,000 $3,216,000 +$1,248,000 +63% 01 Oct 2024 31 Dec 2024 10-K 26 Feb 2025 2024 FY
Q3 2024 $11,855,000 $3,357,000 +$1,317,000 +65% 01 Jul 2024 30 Sep 2024 10-Q 04 Nov 2025 2025 Q3
Q2 2024 $10,538,000 $3,332,000 +$1,110,000 +50% 01 Apr 2024 30 Jun 2024 10-Q 12 Aug 2025 2025 Q2
Q1 2024 $9,428,000 $3,198,000 +$1,523,000 +91% 01 Jan 2024 31 Mar 2024 10-Q 15 May 2025 2025 Q1
Q4 2023 $7,905,000 $1,968,000 -$2,135,000 -52% 01 Oct 2023 31 Dec 2023 10-K 26 Feb 2025 2024 FY
Q3 2023 $10,040,000 $2,040,000 -$2,430,000 -54% 01 Jul 2023 30 Sep 2023 10-Q 13 Nov 2024 2024 Q3
Q2 2023 $12,470,000 $2,222,000 -$1,919,000 -46% 01 Apr 2023 30 Jun 2023 10-Q 12 Aug 2024 2024 Q2
Q1 2023 $14,389,000 $1,675,000 -$3,654,000 -69% 01 Jan 2023 31 Mar 2023 10-Q 14 May 2024 2024 Q1
Q4 2022 $18,043,000 $4,103,000 -$852,000 -17% 01 Oct 2022 31 Dec 2022 10-K 19 Mar 2024 2023 FY
Q3 2022 $18,895,000 $4,470,000 -$616,000 -12% 01 Jul 2022 30 Sep 2022 10-Q 14 Nov 2023 2023 Q3
Q2 2022 $19,511,000 $4,141,000 -$408,000 -9% 01 Apr 2022 30 Jun 2022 10-Q 14 Aug 2023 2023 Q2
Q1 2022 $19,919,000 $5,329,000 +$1,735,000 +48% 01 Jan 2022 31 Mar 2022 10-Q 11 May 2023 2023 Q1
Q4 2021 $18,184,000 $4,955,000 01 Oct 2021 31 Dec 2021 10-K 28 Mar 2023 2022 FY
Q3 2021 $5,086,000 +$3,745,000 +279% 01 Jul 2021 30 Sep 2021 10-Q 08 Nov 2022 2022 Q3
Q2 2021 $4,549,000 01 Apr 2021 30 Jun 2021 10-Q 11 Aug 2022 2022 Q2
Q1 2021 $3,594,000 01 Jan 2021 31 Mar 2021 10-Q 16 May 2022 2022 Q1
Q3 2020 $1,341,000 01 Jul 2020 30 Sep 2020 10-Q 10 Nov 2021 2021 Q3

Taysha Gene Therapies, Inc. Annual Share-based Payment Arrangement, Expense (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
2024 $13,103,000 +$5,198,000 +66% 01 Jan 2024 31 Dec 2024 10-K 26 Feb 2025 2024 FY
2023 $7,905,000 -$10,138,000 -56% 01 Jan 2023 31 Dec 2023 10-K 26 Feb 2025 2024 FY
2022 $18,043,000 -$141,000 -0.78% 01 Jan 2022 31 Dec 2022 10-K 19 Mar 2024 2023 FY
2021 $18,184,000 +$14,830,000 +442% 01 Jan 2021 31 Dec 2021 10-K 28 Mar 2023 2022 FY
2020 $3,354,000 01 Jan 2020 31 Dec 2020 10-K 31 Mar 2022 2021 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.